Orum Therapeutics
Olaf Christensen has an extensive work experience in the pharmaceutical and medical field. Olaf is currently working as the Chief Medical Officer at Orum Therapeutics, a position they have held since October 2021. Prior to this, they also served as the Chief Medical Officer at the same company. From 2015 to 2021, Olaf worked at EMD Serono, Inc. where they held the position of Vice President from December 2018 to September 2021, and Executive Medical Director from November 2015 to November 2018. Before joining EMD Serono, Inc., they worked at Bristol-Myers Squibb, Princeton, New Jersey as a Group Director from November 2011 to October 2015. Olaf's career began at Bayer Pharmaceuticals in 2004, where they served as the Deputy Director of Oncology until November 2011. Prior to that, they worked as an attending physician, Clinic for Medical Oncology at the University of Heidelberg from September 1999 to February 2004. Olaf's professional journey started at the University of Cologne where they served as an Arzt im Praktikum from 1997 to 1999.
Olaf Christensen pursued their education at the University of Cologne from 1990 to 1997, where they earned a degree in medicine. Olaf'sfield of study during this period was focused on medicine.
This person is not in any offices
Orum Therapeutics
Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibodytherapeutics. In contrast to other approaches, Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification.